(Q28377537)

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Reserpine-insensitive dopamine release in the substantia nigra?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease--a critical analysis of the neurochemical evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Biochemical aspects of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Does reserpine induce parkinsonian rigidity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

The behavioural effects of pramipexole, a novel dopamine receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Evidence for a quantitative association between EMG stretch responses and Parkinsonian rigidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

The role of reflex activity in the regulation of muscle tone in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

A functional test identifies dopamine agonists selective for D3 versus D2 receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9

D-1 and D-2 agonists in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2899%2900704-9